Dr. Reddy's Laboratories Launches Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the US Market
8 September 2020 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched in the US market Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe, a therapeutic equivalent generic version of Faslodex (fulvestrant) Injection, 250 mg/5 mL (50 mg/mL), approved by the US Food and Drug Administration (USFDA), the company said.

The Faslodex brand and generic market had US sales of approximately USD 407m MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.

Dr. Reddy's Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe is available in a carton containing two 5 mL single-dose prefilled syringes.

Dr. Reddy's Laboratories is an integrated pharmaceutical company.

Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. The company's major markets include USA, India, Russia and CIS countries, and Europe.